Basilea’s co-development partner Astellas Pharma Inc. also recently submitted a New Drug Application (NDA) for isavuconazole to the U.S. Food and Drug Administration (FDA). Ronald Scott, Basilea’s Chief
The Phase 1/2 study, taking place at Tampere Hospital in Finland, a world-leading site for celiac disease research, is a two-part (single and repeated administration), double-blind, placebo-controlled, dose
Previously, NexoBrid received marketing authorization from the European Medicines Agency for this same indication in the European Union (EU), and the product was commercially launched. "We are especially
ISIS-TTRRx is an antisense drug in development with GSK for the treatment of transthyretin amyloidosis, a severe and rare genetic disease characterized by progressive dysfunction of peripheral nerve
Preclinical studies have shown that IQP-0528 is highly effective against virus strains found throughout the world, prevents HIV transmission in cultured cells, causes sterilization of cultures infected with
The study will engage the laboratory of Dr. Charles Brenner, Roy J. Carver Chair of Biochemistry and Professor of Internal Medicine at University of Iowa. Brenner, is credited
Celsion’s reagent products are based on its newly acquired proprietary delivery platform technologies, TheraPlas and TheraSilence. TheraPlas and TheraSilence are designed for optimal transfection (intra-cellular delivery) of plasmid
The new line contains 44 vitamins and supplements with various benefits, including popular options such as probiotics, B-12, and multivitamins for both men and women. The radiance PLATINUM
The five-year APOE4 trial will involve more than 1,300 cognitively healthy older adults, ages 60 to 75, at high risk of developing symptoms of Alzheimer’s because they inherited
The Fast Track program of the FDA is designed to expedite the development and review of new drugs that are intended to treat serious or life-threatening conditions and
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.